J&J fined $1bn over selling of Risperdal drug

 
City A.M. Reporter
JOHNSON & Johnson (J&J) was yesterday fined $1.1bn (£691m) for misleading patients and doctors about risks associated with its anti-psychotic drug Risperdal.

Dustin McDaniel, attorney-general for Arkansas, where the case was bought, said J&J engaged in “deceptive” practices when marketing its Risperdal drug.